Author: Jane Edwards|| Date Published: December 8, 2020
Palantir Technologies (NYSE: PLTR) has received a potential three-year, $44.4M contract from the Food and Drug Administration to provide software that could be used to analyze data associated with drug reviews and inspections, Bloomberg reported Monday.
The FDA’s Center for Drug Evaluation and Research and the Oncology Center of Excellence will use Palantir software to facilitate the approval process for potential COVID-19 treatments and other drugs and track the safety of hand sanitizers and other items.
The report said government work now accounts for more than half of Palantir’s total revenue. The company is working on software for a new system – Tiberius – that could help federal health officials track the production, distribution and administration of COVID-19 vaccines.
Palantir went public through a direct listing in September and received a valuation of approximately $21B during its trading debut.
Government IT services contractor Aretum has promoted Amy French, most recently chief accounting officer, to chief financial officer. Vienna, Virginia-based…
Shield AI has agreed to acquire simulation software company Aechelon Technology as part of efforts to expand its technological capabilities. The San Diego-based…
SentinelOne, a company specializing in artificial intelligence security, has promoted Barry Padgett to president and chief operating officer. The appointment takes effect…
Anduril Industries and Palantir Technologies are helping develop software for the potential $185 billion Golden Dome next-generation missile defense shield,…
